Published online before print September 9, 2002, doi: 10.1161/01.CIR.0000030185.67510.C0
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1664.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis
From the Vasculitis Research Unit, Department of Internal Medicine, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (M.C.C., J.H.-R., M.-J.E., M.C., C.F., A.U.-M., J.M.G.); and the Craniofacial Development and Regeneration Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md (Y.S.G., H.K.K.).
Correspondence to Maria C. Cid, MD, Department of Internal Medicine, Hospital Clínic, Villarroel 170, 08036-Barcelona, Spain. E-mail mccid{at}clinic.ub.es
Background— Vascular inflammatory lesions from patients with giant-cell arteritis show a remarkable amount of neovascularization, but its clinical implications have never been investigated.
Methods and Results— To assess the clinical relevance of neovascularization in giant-cell arteritis, angiogenesis was measured in temporal artery sections from 31 patients with biopsy-proven giant-cell arteritis by staining endothelial cells with Ulex europaeus lectin. Angiogenesis was highly variable among these patients. Patients without ischemic complications had higher tissue angiogenesis scores than patients with ischemic events (5.69±0.6 versus 2.91±0.6, P=0.003). Angiogenesis was also more prominent in patients with a strong acute phase response (score: 5.31±0.6) compared with those with a weak systemic inflammatory reaction (2.30±0.44; P=0.0007). Serum angiogenic activity was studied in an additional series of 38 biopsy-proven patients. Sera from patients without ischemic events tended to be more active in stimulating human umbilical vein endothelial cell growth (optical density x1000, 270±15 versus 192±14, P=0.065) and differentiation into capillary-like structures (107±5 versus 84±8 relative units, P=0.0058) than patients with ischemic complications. Sera from patients without ischemic events had more in vivo full angiogenic activity tested in the chick chorioallantoic membrane than sera from patients with ischemic complications.
Conclusion— Inflammation-induced angiogenic activity may play a compensatory role for ischemia in patients with giant-cell arteritis.
Key Words: angiogenesis • inflammation • vasculature
This article has been cited by other articles:
 |
|
 |
|
  G. S. D. Marco, S. Reuter, U. Hillebrand, S. Amler, M. Konig, E. Larger, H. Oberleithner, E. Brand, H. Pavenstadt, and M. Brand The Soluble VEGF Receptor sFlt1 Contributes to Endothelial Dysfunction in CKD J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2235 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Salvarani, C. D. Bella, L. Cimino, P. Macchioni, D. Formisano, G. Bajocchi, N. Pipitone, M. G. Catanoso, G. Restuccia, A. Ghinoi, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis Rheumatology, March 1, 2009; 48(3): 250 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. PALOMINO-MORALES, T. R. VAZQUEZ-RODRIGUEZ, J. A. MIRANDA-FILLOY, J. MARTIN, and M. A. GONZALEZ-GAY C-Reactive Protein Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis from Northwestern Spain J Rheumatol, February 1, 2009; 36(2): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Chatelain, P Duhaut, J Schmidt, R Loire, S Bosshard, M Guernou, H Pellet, J C Piette, H Sevestre, J P Ducroix, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss Ann Rheum Dis, January 1, 2009; 68(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Lozano, M Segarra, A Garcia-Martinez, J Hernandez-Rodriguez, and M C Cid Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis Ann Rheum Dis, November 1, 2008; 67(11): 1581 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Segarra, A. Garcia-Martinez, M. Sanchez, J. Hernandez-Rodriguez, E. Lozano, J. M Grau, and M. C Cid Gelatinase expression and proteolytic activity in giant-cell arteritis Ann Rheum Dis, November 1, 2007; 66(11): 1429 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hamada, M. K. Kim, A. Iwakura, M. Ii, T. Thorne, G. Qin, J. Asai, Y. Tsutsumi, H. Sekiguchi, M. Silver, et al. Estrogen Receptors {alpha} and {beta} Mediate Contribution of Bone Marrow-Derived Endothelial Progenitor Cells to Functional Recovery After Myocardial Infarction Circulation, November 21, 2006; 114(21): 2261 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Cid, M. P. Hoffman, J. Hernandez-Rodriguez, M. Segarra, M. Elkin, M. Sanchez, C. Vilardell, A. Garcia-Martinez, M. Pla-Campo, J. M. Grau, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis Rheumatology, November 1, 2006; 45(11): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Lohr, D. C. Warltier, W. M. Chilian, and D. Weihrauch Haptoglobin expression and activity during coronary collateralization Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1389 - H1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hernandez-Rodriguez, M. Segarra, C. Vilardell, M. Sanchez, A. Garcia-Martinez, M.-J. Esteban, J. M. Grau, A. Urbano-Marquez, D. Colomer, H. K. Kleinman, et al. Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis: Angiogenic Activity of Interleukin-6 as a Potential Protective Mechanism Circulation, May 20, 2003; 107(19): 2428 - 2434. [Abstract] [Full Text] [PDF]
|
|